Diaryl dihydropyrazole-3-carboxamides with significant in vivo antiobesity activity related to CB1 receptor antagonism: synthesis, biological evaluation, and molecular modeling in the homology model.

A number of analogues of diaryl dihydropyrazole-3-carboxamides have been synthesized. Their activities were evaluated for appetite suppression and body weight reduction in animal models. Depending on the chemical modification of the selected dihydropyrazole scaffold, the lead compounds--the bisulfate salt of (+/-)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-3-carboxylic acid morpholin-4-ylamide 26 and the bisulfate salt of (-)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-3-carboxylic acid morpholin-4-ylamide 30--showed significant body weight reduction in vivo, which is attributed to their CB1 antagonistic activity and exhibited a favorable pharmacokinetic profile. The molecular modeling studies also showed interactions of two isomers of (+/-)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-3-carboxylic acid morpholin-4-ylamide 9 with CB1 receptor in the homology model similar to those of N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-3-pyrazole-carboxamide (rimonabant) 1 and 4S-(-)-3-(4-chlorophenyl)-N-methyl-N'-[(4-chlorophenyl)-sulfonyl]-4-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamidine (SLV-319) 2.

[1]  D. Lynch,et al.  N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor. , 2002, Molecular pharmacology.

[2]  R. Mechoulam,et al.  Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs , 1991, Pharmacology Biochemistry and Behavior.

[3]  Axel Reinhard Stoit,et al.  Design, synthesis and biological activity of rigid cannabinoid CB1 receptor antagonists. , 2002, Chemical & pharmaceutical bulletin.

[4]  P. Casti,et al.  Synthesis and Characterization of NESS 0327: A Novel Putative Antagonist of the CB1 Cannabinoid Receptor , 2003, Journal of Pharmacology and Experimental Therapeutics.

[5]  Tiziano Tuccinardi,et al.  Cannabinoid CB2/CB1 selectivity. Receptor modeling and automated docking analysis. , 2006, Journal of medicinal chemistry.

[6]  J. Lange,et al.  Keynote review: Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists. , 2005, Drug discovery today.

[7]  R. Pertwee.  The ring test: a quantitative method for assessing the ‘cataleptic’ effect of cannabis in mice , 1972, British journal of pharmacology.

[8]  M. Mahmoudian,et al.  The cannabinoid receptor: computer-aided molecular modeling and docking of ligand. , 1997, Journal of molecular graphics & modelling.

[9]  R. Palmiter,et al.  Leptin-regulated endocannabinoids are involved in maintaining food intake , 2001, Nature.

[10]  K. Jørgensen,et al.  Direct asymmetric Michael reactions of cyclic 1,3-dicarbonyl compounds and enamines catalyzed by chiral bisoxazoline-copper(II) complexes. , 2003, The Journal of organic chemistry.

[11]  Hongtao Yu,et al.  Polyfunctional (R)-2-hydroxycarboxylic acids by reduction of 2-oxo acids with hydrogen gas or formate and resting cells of proteus vulgaris , 1991 .

[12]  Maria Jesus Martin,et al.  The SWISS-PROT protein knowledgebase and its supplement TrEMBL in 2003 , 2003, Nucleic Acids Res..

[13]  J. Lange,et al.  Bioisosteric replacements of the pyrazole moiety of rimonabant: synthesis, biological properties, and molecular modeling investigations of thiazoles, triazoles, and imidazoles as potent and selective CB1 cannabinoid receptor antagonists. , 2005, Journal of medicinal chemistry.

[14]  T. Kirkham,et al.  Endogenous cannabinoids and appetite , 2001, Nutrition Research Reviews.

[15]  J. Ballesteros,et al.  Agonist alkyl tail interaction with cannabinoid CB1 receptor V6.43/I6.46 groove induces a helix 6 active conformation , 2002 .

[16]  P. Widdowson,et al.  Down-regulation of cannabinoid-1 (CB-1) receptors in specific extrahypothalamic regions of rats with dietary obesity: a role for endogenous cannabinoids in driving appetite for palatable food? , 2002, Brain Research.

[17]  G. Kennett,et al.  Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats , 2003, Psychopharmacology.

[18]  Antti Poso,et al.  Development of a 3D model for the human cannabinoid CB1 receptor. , 2004, Journal of medicinal chemistry.

[19]  Mary E Abood,et al.  An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding region. , 2003, Journal of medicinal chemistry.

[20]  K. Palczewski,et al.  Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.

[21]  G. Bray.  Obesity: the disease. , 2006, Journal of medicinal chemistry.

[22]  P. Reggio.  Cannabinoid receptors and their ligands: ligand-ligand and ligand-receptor modeling approaches. , 2005, Handbook of experimental pharmacology.

[23]  P. Casellas,et al.  Modulation of CB1 cannabinoid receptor functions after a long-term exposure to agonist or inverse agonist in the Chinese hamster ovary cell expression system. , 1998, The Journal of pharmacology and experimental therapeutics.

[24]  U. Pandit,et al.  NAD(P)H Models 20 , 1985 .

[25]  S. McAllister,et al.  Biarylpyrazole inverse agonists at the cannabinoid CB1 receptor: importance of the C-3 carboxamide oxygen/lysine3.28(192) interaction. , 2006, Journal of medicinal chemistry.

[26]  J. Chen,et al.  Synthesis and activity of 4,5-diarylimidazoles as human CB1 receptor inverse agonists. , 2005, Bioorganic & medicinal chemistry letters.

[27]  G. Scriba,et al.  Synthesis and activity of 1,3,5-triphenylimidazolidine-2,4-diones and 1,3,5-triphenyl-2-thioxoimidazolidin-4-ones: characterization of new CB1 cannabinoid receptor inverse agonists/antagonists. , 2006, Journal of medicinal chemistry.

[28]  Donald L. Hertzog.  Recent advances in the cannabinoids , 2004 .

[29]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[30]  R. Pertwee.  The pharmacology of cannabinoid receptors and their ligands: an overview , 2006, International Journal of Obesity.

[31]  J. Pinkney,et al.  Control of obesity through the regulation of appetite , 2004 .

[32]  G. Muccioli,et al.  Current knowledge on the antagonists and inverse agonists of cannabinoid receptors. , 2005, Current medicinal chemistry.

[33]  D. A. Whiting,et al.  Synthetic studies on O-heterocycles via cycloadditions. Part 2. Adducts from styrene oxides , 1990 .

[34]  N. Campillo,et al.  Homology models of the cannabinoid CB1 and CB2 receptors. A docking analysis study. , 2005, European journal of medicinal chemistry.

[35]  S. Grundy,et al.  Obesity, metabolic syndrome, and cardiovascular disease. , 2004, The Journal of clinical endocrinology and metabolism.

[36]  J. Lange,et al.  Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB(1) cannabinoid receptor antagonists. , 2004, Journal of medicinal chemistry.

[37]  F Xavier Pi-Sunyer,et al.  Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. , 2006, JAMA.

[38]  V. Marzo,et al.  Endocannabinoid control of food intake and energy balance , 2005, Nature Neuroscience.

[39]  William J Welsh,et al.  Homology model of the CB1 cannabinoid receptor: Sites critical for nonclassical cannabinoid agonist interaction , 2003, Biopolymers.

[40]  G. Nomikos,et al.  The relationship of in vivo central CB1 receptor occupancy to changes in cortical monoamine release and feeding elicited by CB1 receptor antagonists in rats , 2005, Psychopharmacology.

[41]  E. Campaigne,et al.  The Use of Dimethylformamide as a Formylation Reagent1 , 1953 .

[42]  P. Soubrié,et al.  Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors , 1997, Psychopharmacology.